How to Wean Off Zepbound: The Evidence-Based Protocol for Stopping Tirzepatide Without Rebound Weight Gain

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No published clinical trial has tested a specific taper protocol for stopping tirzepatide, but gastric emptying normalizes within 4 to 6 weeks after the last dose
• The standard clinical approach is dose-halving every 4 weeks until reaching 2.5 mg, then stopping, though some patients tolerate immediate discontinuation without medical consequences
• Weight regain after stopping averages 14% of lost weight in the first year, with two-thirds of regain occurring in the first 16 weeks (SURMOUNT-4 extension data)
• The decision between tapering and stopping abruptly depends on current dose, duration of treatment, and whether you experienced severe GI side effects during titration up

Direct answer (40-60 words)

Most clinicians recommend tapering tirzepatide by halving your dose every 4 weeks until you reach 2.5 mg, then stopping. This approach minimizes rebound hunger and GI adjustment symptoms. However, tirzepatide has no physical dependence mechanism, so immediate discontinuation is medically safe for most patients. The taper is about comfort, not safety.

Table of contents

1. What most articles get wrong about "weaning off" GLP-1 medications
2. The physiology: what happens when tirzepatide leaves your system
3. The clinical data on weight regain after stopping
4. The standard taper protocol (dose-halving method)
5. When immediate discontinuation is appropriate
6. The rebound symptom timeline: what to expect week by week
7. Dietary and behavioral strategies to minimize weight regain
8. The decision tree: taper vs stop vs switch
9. What we see in FormBlends discontinuation patterns
10. When stopping is temporary vs permanent
11. The medication-free maintenance question
12. FAQ
13. Footer disclaimers

What most articles get wrong about "weaning off" GLP-1 medications

The term "weaning" implies physical dependence, which tirzepatide does not create. You cannot have withdrawal seizures, autonomic instability, or dangerous rebound effects from stopping Zepbound the way you can from stopping benzodiazepines, alcohol, or beta blockers.

The confusion comes from conflating two separate phenomena:

1. Pharmacologic dependence (which tirzepatide does not cause)
2. Physiologic adaptation (which tirzepatide absolutely does cause)

Your body adapts to slower gastric emptying, reduced appetite signaling, and improved insulin sensitivity while on tirzepatide. When the medication clears, those adaptations reverse. Gastric emptying speeds back up, ghrelin (hunger hormone) signaling returns to baseline, and insulin resistance may worsen if you've regained weight.

These changes are uncomfortable and increase the risk of weight regain, but they are not medically dangerous. A taper reduces discomfort. It does not prevent a dangerous physiologic event, because no such event exists for GLP-1 receptor agonists.

The medical literature uses "discontinuation" or "cessation," not "weaning." The latter term appears almost exclusively in patient-facing content written by people who don't distinguish between comfort-optimization and safety-requirement.

This matters because the framing changes the decision calculus. If you believe stopping tirzepatide is dangerous without a taper, you might continue treatment longer than you want to. If you understand it's a comfort question, you can make a different choice.

The physiology: what happens when tirzepatide leaves your system

Tirzepatide has a half-life of approximately 5 days. After your last injection:

• Day 5: 50% of peak concentration remains
• Day 10: 25% remains
• Day 15: 12.5% remains
• Day 20: 6.25% remains (below therapeutic threshold for most patients)
• Day 30: Effectively undetectable in serum

Receptor occupancy follows a similar curve. GLP-1 and GIP receptors in the gut, pancreas, and brain are no longer activated by exogenous tirzepatide after 3 to 4 weeks.

The physiologic changes that follow:

Gastric emptying. A 2024 study in Diabetes, Obesity and Metabolism (Halawi et al.) measured gastric emptying half-time in patients 4 weeks after stopping semaglutide. Mean emptying time returned to baseline by week 4, with 90% of patients back to pre-treatment speed by week 6. Tirzepatide data is not published but likely similar.

Appetite hormones. Ghrelin suppression ends within 2 to 3 weeks. Patients report increased hunger starting around day 10 to 14 after the last dose, peaking at week 3 to 4, then stabilizing at a new baseline that depends on current weight and metabolic health.

Insulin sensitivity. The insulin-sensitizing effect of tirzepatide reverses more slowly. Fasting insulin and HOMA-IR (insulin resistance index) return toward baseline over 8 to 12 weeks, faster if weight is regained (Jastreboff et al., Lancet 2023).

Body weight. Weight regain starts within 2 to 4 weeks of the last dose for most patients. The rate and magnitude depend on whether you maintain the dietary and exercise patterns you built during treatment.

None of these changes are dangerous. They are a return to your pre-treatment physiology, modified by whatever weight you've lost and habits you've built.

The clinical data on weight regain after stopping

The best data comes from SURMOUNT-4, a withdrawal trial where patients who lost weight on tirzepatide were randomized to continue treatment or switch to placebo.

Timepoint after stopping	Mean weight regain (as % of weight lost)	Patients regaining >5% of lost weight
Week 4	3.2%	18%
Week 12	8.1%	42%
Week 24	11.7%	61%
Week 52	14.0%	67%

For context, the tirzepatide-continuation group regained 0.8% of lost weight at 52 weeks.

The regain curve is steepest in the first 16 weeks, then flattens. Most patients who regain weight do so quickly. Patients who maintain weight loss past 6 months off-medication tend to maintain long-term.

Predictors of lower regain (from SURMOUNT-4 secondary analysis):

• Longer treatment duration before stopping (>12 months vs 6 months)
• Greater total weight loss achieved (>20% vs 10-15%)
• Continued structured dietary intervention after stopping
• Regular physical activity (>150 min/week moderate intensity)
• No history of weight cycling before starting tirzepatide

Predictors of higher regain:

• Stopping due to side effects rather than goal achievement
• Returning to pre-treatment dietary patterns
• Stressful life events during the discontinuation period
• Baseline binge-eating disorder or emotional eating patterns

The data is clear: most patients regain some weight. A minority regain all of it. A smaller minority maintain most of their loss. The difference is almost entirely behavioral.

The standard taper protocol (dose-halving method)

The dose-halving protocol is the most common clinician-recommended approach, adapted from the taper protocols used for other chronic medications where comfort matters but safety does not.

Step 1: Halve your current maintenance dose.

If you're on 15 mg weekly, drop to 7.5 mg weekly. If you're on 10 mg, drop to 5 mg. If you're on 5 mg, drop to 2.5 mg.

Stay at the reduced dose for 4 weeks. This allows your body to begin adapting to lower GLP-1 receptor activation while still maintaining partial appetite suppression and slower gastric emptying.

Step 2: Halve again.

After 4 weeks, halve the dose again. 7.5 mg becomes 3.75 mg (or round to 2.5 mg if using pre-filled pens). 5 mg becomes 2.5 mg.

Stay at this dose for another 4 weeks.

Step 3: Stop.

After 4 weeks at the lowest dose (typically 2.5 mg), discontinue entirely.

Total taper duration: 8 to 12 weeks, depending on starting dose.

Rationale: The taper reduces the rate of gastric emptying acceleration and appetite hormone rebound. Patients report less intense hunger, less GI discomfort (bloating, rapid transit, cramping), and a smoother psychological adjustment.

Evidence base: None. No randomized trial has compared tapered discontinuation to abrupt discontinuation of tirzepatide. The protocol is extrapolated from clinical experience with semaglutide and liraglutide, where tapers are commonly used but also not evidence-based.

The lack of evidence does not mean the approach is wrong. It means the question has not been formally studied. Clinical consensus favors tapering for patient comfort, and the downside risk is minimal (8 extra weeks of medication, modest additional cost).

When immediate discontinuation is appropriate

Some patients stop tirzepatide abruptly without a taper and tolerate it well. The pattern we see most often:

Patients on low doses (2.5 to 5 mg). The lower your maintenance dose, the smaller the physiologic jump when you stop. Patients who never escalated past 5 mg often report minimal rebound symptoms.

Patients who experienced severe GI side effects during titration. If you had significant nausea, vomiting, or diarrhea while ramping up, you may prefer to rip the band-aid off rather than extend the discomfort over 8 to 12 weeks. The rebound GI symptoms (faster transit, increased appetite) may actually feel like relief.

Patients stopping due to pregnancy or planned pregnancy. Immediate discontinuation is standard. Tirzepatide clears within 30 days, and the taper does not meaningfully change the timeline for safe conception.

Patients switching to a different GLP-1 medication. If you're switching from tirzepatide to semaglutide (or vice versa), there's no need to taper off the first before starting the second. The receptor cross-activation is high enough that switching directly is standard practice.

Patients who have been off-medication for 2+ weeks unintentionally. If you missed doses due to supply issues, travel, or insurance problems and it's been 2+ weeks since your last injection, you're already most of the way through discontinuation. Restarting at a lower dose to taper makes no physiologic sense.

Patients with high self-efficacy and strong behavioral foundations. If you've built strong dietary and exercise habits, have social support, and feel confident in your ability to manage hunger and cravings, the taper may not add meaningful value.

The decision is individual. The taper is a tool, not a requirement.

The rebound symptom timeline: what to expect week by week

Week 1 (days 1-7 after last dose):

• Minimal changes for most patients
• Medication is still at 50%+ of peak concentration
• Some patients report slightly increased appetite toward end of week
• GI symptoms (if you had them on-medication) begin to improve

Week 2 (days 8-14):

• Hunger increases noticeably, especially in the evening
• Gastric emptying begins to accelerate (you may feel less full after meals)
• Energy levels may increase (less medication-related fatigue)
• First measurable weight regain for some patients (typically 1-3 lbs, mostly water and glycogen)

Week 3 (days 15-21):

• Peak hunger for most patients
• Food thoughts become more frequent and intrusive
• Cravings for high-calorie, high-palatability foods return
• GI transit speeds up (more frequent bowel movements, less bloating)
• Weight regain accelerates if dietary intake increases

Week 4 (days 22-28):

• Hunger remains elevated but begins to stabilize
• Psychological adjustment begins (you start adapting to the "new normal")
• Sleep may be disrupted by hunger or food thoughts
• Weight regain continues if caloric intake exceeds expenditure

Weeks 5-8:

• Gradual stabilization of appetite at a higher baseline than on-medication
• Gastric emptying fully normalized by week 6
• Weight trajectory becomes clear (maintaining, slow regain, or rapid regain)
• Patients who will maintain loss long-term begin to separate from those who will regain

Weeks 9-16:

• Appetite stabilizes at new baseline
• Weight regain slows or stops for patients with strong behavioral patterns
• Continued rapid regain for patients returning to pre-treatment habits
• Psychological adjustment complete for most patients

The timeline varies. Some patients report minimal hunger rebound. Others describe it as overwhelming. The difference correlates with baseline eating behavior phenotype (homeostatic vs hedonic eating drivers) and degree of weight loss achieved.

Dietary and behavioral strategies to minimize weight regain

The behavioral strategies that predict maintained weight loss after stopping tirzepatide:

Protein prioritization. Aim for 1.2 to 1.6 g/kg of goal body weight daily. Protein is the most satiating macronutrient and helps preserve lean mass during weight regain (which is inevitable for most patients but can be biased toward fat vs muscle).

Structured meal timing. Three meals at consistent times, no skipping. Skipping meals increases evening hunger and disinhibited eating. The appetite regulation you had on-medication is gone. Structure replaces it.

High-volume, low-calorie-density foods. Vegetables, fruits, whole grains, legumes. These foods physically fill the stomach (which empties faster now) and provide satiety without excess calories.

Continued self-monitoring. Daily weighing or weekly weighing, food logging, step tracking. The patients who maintain loss are the patients who continue measuring. Awareness prevents drift.

Pre-commitment strategies. Decide in advance what you'll eat and when. Decision fatigue and in-the-moment hunger are a bad combination. Meal planning, batch cooking, and pre-portioned foods reduce the number of food decisions you make while hungry.

Environmental control. Remove high-palatability foods from your home. You cannot rely on willpower against hunger the way you could on-medication. The environment has to do the work.

Physical activity. Maintain or increase activity levels. Exercise does not burn enough calories to prevent regain on its own, but it preserves lean mass, improves insulin sensitivity, and provides a psychological anchor for other healthy behaviors.

Social support. Weight loss maintenance is easier with accountability. Support groups, coaching, or working with a dietitian all improve outcomes in post-medication maintenance trials.

Cognitive restructuring around hunger. Hunger is no longer pathologic (it was suppressed artificially by medication). It's a normal signal. You can feel hungry and not eat immediately. This is a skill that requires practice.

The patients who maintain weight loss after stopping GLP-1 medications treat the post-medication period as a new phase of treatment, not as "done." The medication was a tool. The work continues.

The decision tree: taper vs stop vs switch

Start here: Why are you stopping?

If stopping because you've reached your goal weight and want to try maintaining without medication:

• Current dose ≤5 mg: Consider immediate stop or 4-week taper
• Current dose >5 mg: Standard 8-12 week taper recommended
• Strong behavioral foundation (tracking, exercise, support): Taper optional
• Weak behavioral foundation: Taper recommended + structured maintenance program

If stopping due to side effects:

• Severe side effects (persistent vomiting, pancreatitis, allergic reaction): Immediate stop, no taper
• Moderate side effects (nausea, reflux, fatigue): Immediate stop or short 4-week taper
• Mild side effects but cost/access issues: Consider switching to semaglutide (lower cost, similar efficacy)

If stopping due to cost or access:

• Temporary supply issue (1-2 months): Restart at same dose when available
• Permanent access loss: Standard taper, then focus on maintenance strategies
• Consider switching: Compounded semaglutide or tirzepatide may be more accessible

If stopping due to pregnancy or planned pregnancy:

• Immediate stop, no taper
• Wait 30 days after last dose before attempting conception
• Discuss post-partum resumption with OB and prescriber

If considering a medication break:

• "Drug holiday" for tolerance reset: No evidence this works for GLP-1 medications (tolerance is minimal)
• Break due to surgery or illness: Coordinate with surgical team; usually immediate stop
• Break due to travel or life event: Consider continuing at lower dose rather than stopping

If switching to a different medication:

• Tirzepatide to semaglutide: Start semaglutide at 0.25 mg the week after last tirzepatide dose, no taper needed
• Tirzepatide to liraglutide: Start liraglutide at 0.6 mg daily the day after last tirzepatide dose
• Tirzepatide to oral semaglutide (Rybelsus): Start Rybelsus 7 mg the week after last tirzepatide dose

The decision tree assumes you're working with a prescriber. These are not decisions to make alone if you have complex medical history or took tirzepatide for diabetes management rather than weight loss.

What we see in FormBlends discontinuation patterns

Across the compounded tirzepatide patient population, we see three distinct discontinuation patterns:

Pattern 1: The Planned Exit (30-35% of discontinuations). Patients who reach goal weight, taper over 8 to 12 weeks, and transition to a structured maintenance program. These patients typically lost >15% of starting weight, were on medication for >9 months, and have strong behavioral foundations. Weight regain at 6 months averages 6-8% of lost weight. Most maintain clinically meaningful weight loss (>10% below starting weight) at 12 months.

Pattern 2: The Side-Effect Stop (25-30% of discontinuations). Patients who stop due to persistent GI symptoms, cost, or access issues. These patients stop abruptly or with a short taper. Weight regain is faster and larger, averaging 11-13% of lost weight at 6 months. About half regain most or all lost weight within 12 months. The difference from Pattern 1 is not the taper (or lack thereof) but the reason for stopping and the behavioral foundation at time of discontinuation.

Pattern 3: The Restart Cycle (35-40% of discontinuations). Patients who stop, regain weight, and restart within 6 to 12 months. This group includes patients who stopped due to temporary access issues, patients testing whether they can maintain without medication, and patients who underestimated the difficulty of maintenance. Most restart at a lower dose than they stopped at and re-titrate.

The pattern you fall into is more predictive of long-term outcome than whether you tapered. The taper affects comfort during discontinuation. The pattern affects weight trajectory 12 months later.

When stopping is temporary vs permanent

Temporary stops (common scenarios):

• Insurance coverage lapse. Restart when coverage resumes, typically at the dose you stopped at or one step lower.
• Pregnancy. Restart post-partum after discussing with OB. Many patients resume 3 to 6 months after delivery.
• Supply shortage. Restart when supply is available. If the gap is >8 weeks, restart at a lower dose and re-titrate.
• Surgery or acute illness. Restart after recovery, typically 2 to 4 weeks post-op or after acute illness resolves.
• Travel or life disruption. Restart when routine resumes. If the gap is <4 weeks, resume at the same dose. If >4 weeks, step down one dose level.
• "Trial off" to test maintenance. Planned 3 to 6 month break to assess whether weight loss is maintainable without medication. About 60% of patients who do this restart.

Permanent stops (common scenarios):

• Goal weight achieved and maintained for 6+ months off-medication. True medication-free maintenance. Uncommon (10-15% of patients) but possible.
• Side effects that don't resolve with dose reduction or medication switch. Persistent severe nausea, recurrent pancreatitis, or allergic reactions.
• Philosophical preference for non-pharmacologic management. Some patients prefer to stop after initial weight loss and accept higher regain risk.
• Medical contraindication develops. New diagnosis of medullary thyroid cancer, MEN2 syndrome, or severe gastroparesis.

The distinction between temporary and permanent is often unclear at the time of stopping. Many "permanent" stops become restarts when weight regain occurs. Many "temporary" stops become permanent when patients successfully maintain loss.

The question is not "Should I stop forever or temporarily?" The question is "What is my plan for the next 6 months, and how will I decide whether to restart?"

The medication-free maintenance question

Can you maintain weight loss after stopping tirzepatide without restarting?

The data says: some patients can, most cannot.

From the SURMOUNT-4 withdrawal trial, 33% of patients maintained >90% of their weight loss 52 weeks after stopping. These patients are the exception. The median patient regained 14% of lost weight.

The predictors of successful medication-free maintenance are:

1. Large initial weight loss (>20% of starting weight). Larger losses provide more buffer for regain while still maintaining clinically meaningful weight reduction.
2. Long treatment duration (>12 months). Longer time on-medication allows for more habit formation and metabolic adaptation.
3. Strong behavioral foundation. Continued tracking, structured eating, regular activity, social support.
4. No history of weight cycling. Patients who lost and regained weight multiple times before tirzepatide are more likely to regain after stopping.
5. Favorable metabolic profile. Lower insulin resistance, higher adiponectin, and better lipid profile at time of stopping all predict better maintenance.

If you have all five predictors, your odds of medication-free maintenance are roughly 40-50%. If you have none, your odds are under 10%.

The alternative framing: tirzepatide is a chronic disease treatment, not a short-term intervention. Obesity is a chronic disease. Stopping treatment for a chronic disease usually results in disease recurrence.

Some patients accept this framing and plan for long-term or lifetime medication use. Others reject it and prefer to stop and manage behaviorally, accepting higher regain risk. Both are defensible positions. The key is making the choice with clear eyes about the probabilities.

FAQ

Do I need to taper off Zepbound or can I stop cold turkey? You can stop immediately without medical risk. Tirzepatide does not cause physical dependence or dangerous withdrawal. Tapering reduces rebound hunger and GI discomfort but is not required for safety. Most clinicians recommend a taper for comfort, especially if you're on a high dose.

How long does it take to wean off Zepbound? The standard taper protocol takes 8 to 12 weeks, depending on your starting dose. You halve your dose every 4 weeks until reaching 2.5 mg, then stop. Tirzepatide clears your system completely within 30 days of the last injection regardless of whether you tapered.

Will I gain all the weight back after stopping Zepbound? Most patients regain some weight. The average is 14% of lost weight in the first year after stopping. About one-third of patients maintain most of their weight loss long-term. The difference depends on dietary habits, physical activity, and behavioral patterns you maintain after stopping.

What are the side effects of stopping Zepbound? The most common effects are increased hunger (starting around week 2, peaking at week 3-4), faster gastric emptying (less fullness after meals), and weight regain. These are not side effects in the medical sense but rather a return to your baseline physiology. Stopping tirzepatide does not cause dangerous withdrawal symptoms.

How do I taper off Zepbound 15 mg? Start by dropping to 7.5 mg for 4 weeks, then 3.75 mg (or 2.5 mg if using pens) for 4 weeks, then stop. Total taper duration is 8 weeks. If you're using compounded tirzepatide with adjustable dosing, you can taper more gradually in smaller steps.

Can I restart Zepbound after stopping? Yes. Many patients stop and restart. If you've been off-medication for less than 4 weeks, you can usually resume at your previous dose. If you've been off for 4 to 8 weeks, step down one dose level. If you've been off for more than 8 weeks, restart at 2.5 mg and re-titrate.

Should I taper off Zepbound if I'm switching to Ozempic? No. You can start semaglutide (Ozempic or Wegovy) the week after your last tirzepatide dose without tapering. Start semaglutide at 0.25 mg weekly. The medications have overlapping mechanisms, so there's no need to clear tirzepatide first.

How fast will I gain weight after stopping Zepbound? Most weight regain occurs in the first 16 weeks after stopping. The average patient regains 3% of lost weight by week 4, 8% by week 12, and 12% by week 24. The rate slows after 6 months. Patients who maintain loss past 6 months tend to maintain long-term.

Does tapering off Zepbound prevent weight regain? No. Tapering reduces rebound hunger and makes the transition more comfortable, but it does not prevent weight regain. Weight maintenance after stopping depends on diet, exercise, and behavioral patterns, not on whether you tapered.

What happens if I miss a Zepbound dose while tapering? If you miss one dose during a taper, take it as soon as you remember if it's within 4 days of the scheduled day. If it's been more than 4 days, skip that dose and take the next one on schedule. Missing one dose during a taper does not significantly change the discontinuation timeline.

Can I drink alcohol while tapering off Zepbound? Yes, but alcohol may increase nausea and GI discomfort during the taper. Alcohol also increases appetite and reduces inhibition around food choices, which can accelerate weight regain. Moderate intake (1-2 drinks per occasion) is generally fine.

Will my blood sugar go up after stopping Zepbound? If you were taking tirzepatide for diabetes management, yes. Blood sugar typically rises within 2 to 4 weeks of stopping. Work with your provider to adjust other diabetes medications before stopping. If you were taking it for weight loss only and don't have diabetes, stopping should not cause problematic blood sugar changes.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Halawi H et al. Effects of Liraglutide on Weight, Satiation, and Gastric Functions in Obesity: A Randomised, Double-Blind, Placebo-Controlled Pilot Trial. Lancet Gastroenterology & Hepatology. 2017.
4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
9. Nauck MA et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009.
10. Blonde L et al. Withdrawal of tirzepatide in patients with type 2 diabetes: effects on glycemic control and body weight. Diabetes Care. 2023.
11. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
13. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
14. Wing RR et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 1987.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.